Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization

Keyphrases

• AIDS/HIV 100%
• Immunogenicity 100%
• Cytotoxic T Cell Response 100%
• Virus Envelope 100%
• Envelope Glycoprotein 100%
• Genetic Immunization 100%
• Glycoprotein 50%
• Monoclonal Antibody 50%
• Antibody Response 50%
• Human Immunodeficiency Virus Type 1 (HIV-1) 50%
• Cytotoxic T Lymphocytes 50%
• (I)-envelope 50%
• Humoral Immune Response 50%
• DNA Vaccination 50%
• Plasmid 50%
• Glycosylation Site 50%
• Humoral Immunity 50%
• Vector Encoding 50%
• Cleavage Site 50%
• Gp160 50%
• Expression Vector 50%
• Specific mutation 50%
• AIDS Vaccine 50%
• Antibody Production 50%
• Virus Neutralization 50%
• Gp140 50%
• Trimer Formation 50%
• Heptad Repeat 50%
• Fusogenic 50%
• Fusion Intermediate 50%
• HIV Envelope 50%
• Oligomer Formation 50%

Immunology and Microbiology

• Glycoprotein 100%
• Human Immunodeficiency Virus 100%
• Immunogenicity 100%
• Viral Envelope 100%
• Cytotoxic T Cell 100%
• Humoral Immunity 66%
• Monoclonal Antibody 33%
• Antibody Response 33%
• Mouse 33%
• Human Immunodeficiency Virus 1 33%
• Carboxy Terminal Sequence 33%
• CD4 33%
• Plasmid 33%
• DNA Vaccination 33%
• Glycosylation 33%
• Expression Vector 33%
• HIV Vaccine 33%
• Antibody Production 33%
• Virus Neutralization 33%